MSC-4106
CAS No. 2738542-58-8
MSC-4106 ( —— )
产品货号. M35343 CAS No. 2738542-58-8
MSC-4106 是一种具有口服活性的 YAP/TAZ-TEAD 抑制剂。 MSC-4106 阻断 TEAD1 和 TEAD3 的 auto-palmitoylation,对 NCI-H226 异种移植瘤模型具有抑制作用。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥2328 | 有现货 |
|
| 10MG | ¥3734 | 有现货 |
|
| 25MG | ¥5831 | 有现货 |
|
| 50MG | ¥7868 | 有现货 |
|
| 100MG | ¥10170 | 有现货 |
|
| 200MG | ¥13770 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥1862 | 有现货 |
|
生物学信息
-
产品名称MSC-4106
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述MSC-4106 是一种具有口服活性的 YAP/TAZ-TEAD 抑制剂。 MSC-4106 阻断 TEAD1 和 TEAD3 的 auto-palmitoylation,对 NCI-H226 异种移植瘤模型具有抑制作用。
-
产品描述MSC-4106 is an orally active and potent inhibitor of YAP/TAZ-TEAD. MSC-4106 inhibits TEAD1 or TEAD3 auto-palmitoylation and shows inhibitory effect on NCI-H226 tumor xenograft model.
-
体外实验MSC-4106 (10 μM, 24 h) inhibited SK-HEP-1 reporter and NCI-266 cell viability with IC50 values of 4 nM and 14 nM, respectively.MSC-4106 (10 μM, 6 h) crystallizes in the P-site of TEAD1, and against TEAD1 or TEAD3 palmitoylation in TEAD-Overexpressing HEK293 Cells by 97.3% and 75.9%, respectively.MSC-4106 (10 μM, 4 d) targets TEAD indicated by a reduction in viability of NCI-H226 cells.Cell Viability Assay Cell Line:NCI-H226 (YAP dependent); SW620 YAP/TAZ KO (Yap-independent) cells Concentration:0, 3, 6, 9, 12, 15, 18, 21, 24, 26, 30 μM Incubation Time:96 hours Result:Showed inhibitory effect to NCI-H226 and general cytotoxic to SW620 (IC50 >30 μM).Immunofluorescence Cell Line:SK-HEP-1Concentration:0, 3, 6, 9, 12, 15, 18, 21, 24, 26, 30 μM Incubation Time:24 hours Result:Inhibited YAP-TEAD interation.
-
体内实验MSC-4106 (100 mg/kg/d; p.o.; 7 d) displays anti-tumor effect with controlled tumor volume and good tolerability with stable body weight in mice.MSC-4106 (1, 5, 100 mg/kg/d; p.o.; 0-72 h) down-regulates Cyr61 (cysteine-rich angiogenic inducer 61) expression, the TEAD-regulated target gene, in tumor lysates at all time points at 100 mg/kg and 24 h at 5 mg/kg.Note: PO studies were performed at 10 mg/kg; MSC-4106 was formulated in 20% Kleptose in 50 mM PBS at pH 7.4.Animal Model:NCI-H226 xenograft model in H2d Rag2 female mice (9-week-old)Dosage:5, 100 mg/kg Administration:Oral gavage; once daily; 32 days Result:Resulted tumor growth controlled with 5 mg/kg while regressed with 100 mg/kg dosing after 32 treatment days.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体YAP
-
研究领域——
-
适应症——
化学信息
-
CAS Number2738542-58-8
-
分子量359.3
-
分子式C18H12F3N3O2
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO 中的溶解度 : 250 mg/mL (695.80 mM; 超声助溶 )
-
SMILESCn1cc2c3cc(ccc3n(-c3ccc(cc3)C(F)(F)F)c2n1)C(O)=O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Timo Heinrich, et al. Optimization of TEAD P-site binding fragment hit into in vivo active lead MSC-4106. J. Med. Chem. 2022, 65, 13, 9206–9229.?
产品手册
关联产品
-
Cap-dependent endonu...
Cap-dependent endonuclease-IN-1 是一种高效的帽依赖内切酶抑制剂,具有口服活性。Cap-dependent endonuclease-IN-1 可用于流感的研究。
-
Ciamexon
Ciamexon (Ciamexone) is a novel immunomodulator that has shown promising results in experimental models of autoimmune disease with little demonstrated cytotoxicity.Ciamexon can be used to study endocrine ophthalmopathies and diabetes mellitus, with slight improvement in ophthalmic disease following short-term administration.
-
CP-316819
CP 316819 是一种有效的糖原磷酸化酶 (GPase) 抑制剂,具有降血糖作用 (对人骨骼肌糖原磷酸化酶 (huSMGPa) 和肝糖原磷酸化酶 (huLGPa) 的 IC50 值分别为 17 nM 和 34 nM)。CP 316819 在正常血糖条件下导致糖原积累,但在葡萄糖浓度较低时允许糖原利用。CP-316819 可防止神经细胞死亡并维持脑电流。
021-51111890
购物车()
sales@molnova.cn

